Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells.

Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL.

J Vis Exp. 2019 May 17;(147). doi: 10.3791/59370.

PMID:
31157760
2.

Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Leick KM, Pinczewski J, Mauldin IS, Young SJ, Deacon DH, Woods AN, Bosenberg MW, Engelhard VH, Slingluff CL Jr.

Cancer Immunol Immunother. 2019 May 27. doi: 10.1007/s00262-019-02345-5. [Epub ahead of print]

PMID:
31134297
3.

Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.

Sullivan MR, Mattaini KR, Dennstedt EA, Nguyen AA, Sivanand S, Reilly MF, Meeth K, Muir A, Darnell AM, Bosenberg MW, Lewis CA, Vander Heiden MG.

Cell Metab. 2019 Jun 4;29(6):1410-1421.e4. doi: 10.1016/j.cmet.2019.02.015. Epub 2019 Mar 21.

PMID:
30905671
4.

KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations.

Liu X, Zhang SM, McGeary MK, Krykbaeva I, Lai L, Jansen DJ, Kales SC, Simeonov A, Hall MD, Kelly DP, Bosenberg MW, Yan Q.

Mol Cancer Ther. 2019 Mar;18(3):706-717. doi: 10.1158/1535-7163.MCT-18-0395. Epub 2018 Dec 6.

PMID:
30523048
5.

Author Correction: Autophagy maintains tumour growth through circulating arginine.

Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY, Lattime E, Rabinowitz JD, White E.

Nature. 2019 Jan;565(7737):E3. doi: 10.1038/s41586-018-0815-6.

PMID:
30523330
6.

Immune Cell and Cell Cluster Phenotyping, Quantitation, and Visualization Using In Silico Multiplexed Images and Tissue Cytometry.

Blenman KRM, Bosenberg MW.

Cytometry A. 2019 Apr;95(4):399-410. doi: 10.1002/cyto.a.23668. Epub 2018 Nov 23.

PMID:
30468565
7.

Autophagy maintains tumour growth through circulating arginine.

Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY, Lattime E, Rabinowitz JD, White E.

Nature. 2018 Nov;563(7732):569-573. doi: 10.1038/s41586-018-0697-7. Epub 2018 Nov 14. Erratum in: Nature. 2018 Dec 6;:.

8.

PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.

Micevic G, Thakral D, McGeary M, Bosenberg MW.

Pigment Cell Melanoma Res. 2019 May;32(3):435-440. doi: 10.1111/pcmr.12745. Epub 2018 Nov 22.

PMID:
30343532
9.

Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.

Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW.

Pigment Cell Melanoma Res. 2019 Mar;32(2):292-302. doi: 10.1111/pcmr.12742. Epub 2018 Oct 22.

PMID:
30281931
10.

Frontiers in pigment cell and melanoma research.

Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB, Chen S, D'Orazio JA, Fujita M, Goh BK, Herlyn M, Indra AK, Larue L, Leachman SA, Le Poole C, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF.

Pigment Cell Melanoma Res. 2018 Nov;31(6):728-735. doi: 10.1111/pcmr.12728. Epub 2018 Oct 3.

11.

Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity.

Ventura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL.

Cancer Res. 2018 Jul 15;78(14):4045-4058. doi: 10.1158/0008-5472.CAN-18-0171. Epub 2018 May 15.

PMID:
29764863
12.

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.

Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW.

J Immunother Cancer. 2017 Sep 19;5(1):77. doi: 10.1186/s40425-017-0278-6.

13.

Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.

Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6157-E6165. doi: 10.1073/pnas.1700363114. Epub 2017 Jul 14.

14.

p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.

Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW.

J Invest Dermatol. 2017 Oct;137(10):2187-2196. doi: 10.1016/j.jid.2016.12.033. Epub 2017 Jun 7.

15.

A Computational Approach for Identifying Synergistic Drug Combinations.

Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O.

PLoS Comput Biol. 2017 Jan 13;13(1):e1005308. doi: 10.1371/journal.pcbi.1005308. eCollection 2017 Jan.

16.

Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.

Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodić N.

Melanoma Res. 2017 Apr;27(2):85-96. doi: 10.1097/CMR.0000000000000315.

17.

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.

Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, Swain SL, Bradley LM.

Immunity. 2016 Jun 21;44(6):1470. doi: 10.1016/j.immuni.2016.05.011. No abstract available.

18.

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW.

Pigment Cell Melanoma Res. 2016 Sep;29(5):590-7. doi: 10.1111/pcmr.12498. Epub 2016 Aug 3.

19.

Keratoacanthoma Shares Driver Mutations with Cutaneous Squamous Cell Carcinoma.

Lim YH, Fisher JM, Bosenberg MW, Choate KA, Ko CJ.

J Invest Dermatol. 2016 Aug;136(8):1737-1741. doi: 10.1016/j.jid.2016.04.002. Epub 2016 Jun 7. No abstract available.

20.

Cell and Tissue Display: An Alternative Multipurpose Tool for Microscopy.

Theodosakis N, Micevic G, Bosenberg MW, Rodić N.

J Histochem Cytochem. 2016 Jul;64(7):403-11. doi: 10.1369/0022155416651065. Epub 2016 Jun 7.

21.

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.

Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, Swain SL, Bradley LM.

Immunity. 2016 May 17;44(5):1190-203. doi: 10.1016/j.immuni.2016.04.015.

22.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

23.

Integrative discovery of CD98 as a melanoma biomarker.

Theodosakis N, Micevic G, Sharma R, Baras AS, Lazova R, Bosenberg MW, Rodić N.

Pigment Cell Melanoma Res. 2016 May;29(3):385-7. doi: 10.1111/pcmr.12464. Epub 2016 Apr 10. No abstract available.

PMID:
26850337
24.

Well-Differentiated Syringofibrocarcinoma in a Patient With Clouston Syndrome.

Odell ID, Lilly E, Reeve K, Bosenberg MW, Milstone LM.

JAMA Dermatol. 2016 Apr;152(4):484-6. doi: 10.1001/jamadermatol.2015.4496. No abstract available.

PMID:
26792110
25.

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P.

Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8.

26.

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.

Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF.

Oncotarget. 2015 Nov 10;6(35):37410-25. doi: 10.18632/oncotarget.6138.

27.

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.

Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, Perales JC, Kleinstein SH, Abel ED, Insogna KL, Feske S, Locasale JW, Bosenberg MW, Rathmell JC, Kaech SM.

Cell. 2015 Sep 10;162(6):1217-28. doi: 10.1016/j.cell.2015.08.012. Epub 2015 Aug 27.

28.

What is a vertebrate pigment cell?

Schartl M, Larue L, Goda M, Bosenberg MW, Hashimoto H, Kelsh RN.

Pigment Cell Melanoma Res. 2016 Jan;29(1):8-14. doi: 10.1111/pcmr.12409. Epub 2015 Nov 3. Review.

PMID:
26247887
29.

Melanosis of the areola and nipple with an atypical pigment network.

Antonov NK, Bosenberg MW, Halasz CL.

Int J Dermatol. 2016 Jul;55(7):811-813. doi: 10.1111/ijd.12898. Epub 2015 Jul 28. No abstract available.

PMID:
26220624
30.

BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.

Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW.

Mol Cancer Ther. 2015 Jul;14(7):1680-92. doi: 10.1158/1535-7163.MCT-15-0080. Epub 2015 May 6.

31.

Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.

Zhang Y, Tian S, Liu Z, Zhang J, Zhang M, Bosenberg MW, Kedl RM, Waldmann TA, Storkus WJ, Falo LD Jr, You Z.

Oncoimmunology. 2014 Dec 15;3(10):e959321. eCollection 2014 Nov.

32.

The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.

Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, Koo AB, Klein M, Liu Z, Bosenberg MW, Stern DF.

Pigment Cell Melanoma Res. 2015 Jul;28(4):417-30. doi: 10.1111/pcmr.12376. Epub 2015 May 6.

33.

Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.

Mann MB, Black MA, Jones DJ, Ward JM, Yew CC, Newberg JY, Dupuy AJ, Rust AG, Bosenberg MW, McMahon M, Print CG, Copeland NG, Jenkins NA.

Nat Genet. 2015 May;47(5):486-95. doi: 10.1038/ng.3275. Epub 2015 Apr 13.

34.

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.

Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E536-45. doi: 10.1073/pnas.1418163112. Epub 2015 Jan 26.

35.

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, Pflicke H, Ji Y, Gros A, Hanada K, Goldlust IS, Mehta GU, Klebanoff CA, Crompton JG, Sukumar M, Morrow JJ, Franco Z, Gattinoni L, Liu H, Wang E, Marincola F, Stroncek DF, Lee CC, Raffeld M, Bosenberg MW, Roychoudhuri R, Restifo NP.

Cancer Immunol Res. 2015 Jan;3(1):37-47. doi: 10.1158/2326-6066.CIR-14-0122. Epub 2014 Oct 30.

36.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2015 May 1;21(9):2138-47. doi: 10.1158/1078-0432.CCR-14-0861. Epub 2014 Oct 14.

37.

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ.

Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.

38.

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA.

Cancer Immunol Res. 2014 Jul;2(7):643-54. doi: 10.1158/2326-6066.CIR-13-0215. Epub 2014 Apr 29.

39.

Isolation and molecular characterization of circulating melanoma cells.

Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA.

Cell Rep. 2014 May 8;7(3):645-53. doi: 10.1016/j.celrep.2014.03.039. Epub 2014 Apr 18.

40.

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.

Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM.

Cancer Res. 2014 Jun 15;74(12):3205-17. doi: 10.1158/0008-5472.CAN-13-3461. Epub 2014 Apr 15.

41.

Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging.

Tichauer KM, Deharvengt SJ, Samkoe KS, Gunn JR, Bosenberg MW, Turk MJ, Hasan T, Stan RV, Pogue BW.

Mol Imaging Biol. 2014 Jun;16(3):372-82. doi: 10.1007/s11307-013-0692-1. Epub 2013 Nov 12.

42.

Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, McMahon M.

J Clin Invest. 2013 Dec;123(12):5104-18. doi: 10.1172/JCI69619. Epub 2013 Nov 8.

43.

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18226-31. doi: 10.1073/pnas.1317577110. Epub 2013 Oct 21.

44.

Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma.

Ni TK, Landrette SF, Bjornson RD, Bosenberg MW, Xu T.

Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3640-9. doi: 10.1073/pnas.1314435110. Epub 2013 Sep 3.

45.

Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.

Wollmann G, Davis JN, Bosenberg MW, van den Pol AN.

J Virol. 2013 Jun;87(12):6644-59. doi: 10.1128/JVI.03311-12. Epub 2013 Apr 3.

46.

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.

Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF.

Cancer Discov. 2013 Jan;3(1):52-67. doi: 10.1158/2159-8290.CD-12-0408. Epub 2012 Dec 13.

47.

An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.

Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE.

Nature. 2012 Nov 15;491(7424):449-53. doi: 10.1038/nature11624. Epub 2012 Oct 31.

48.

Perifollicular fibroma in Birt-Hogg-Dubé syndrome: an association revisited.

Shvartsbeyn M, Mason AR, Bosenberg MW, Ko CJ.

J Cutan Pathol. 2012 Jul;39(7):675-9. doi: 10.1111/j.1600-0560.2012.01929.x.

PMID:
22725638
49.

piggyBac transposon somatic mutagenesis with an activated reporter and tracker (PB-SMART) for genetic screens in mice.

Landrette SF, Cornett JC, Ni TK, Bosenberg MW, Xu T.

PLoS One. 2011;6(10):e26650. doi: 10.1371/journal.pone.0026650. Epub 2011 Oct 21.

50.

Colonic ganglioneuromatous polyposis and metastatic adenocarcinoma in the setting of Cowden syndrome: a case report and literature review.

Trufant JW, Greene L, Cook DL, McKinnon W, Greenblatt M, Bosenberg MW.

Hum Pathol. 2012 Apr;43(4):601-4. doi: 10.1016/j.humpath.2011.06.022. Epub 2011 Oct 21. Review.

PMID:
22018627

Supplemental Content

Loading ...
Support Center